| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911263 | Lung Cancer | 2012 | 5 Pages |
Abstract
This trial did not meet its pre-specified response endpoint. A higher cediranib dose level was associated with improved disease control, but this dose was poorly tolerated.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Nicholas P. Campbell, Rangesh Kunnavakkam, Natasha Leighl, Mark D. Vincent, David R. Gandara, Marianna Koczywas, Barbara J. Gitlitz, Edem Agamah, Sachdev P. Thomas, Walter M. Stadler, Everett E. Vokes, Hedy L. Kindler,